Business
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
CREXONT now available in U.S. pharmacies nationwide Comprehensive access and affordability services to be made available to Parkinson’s patients and
About this update from Amneal Pharmaceuticals, Inc.
[{"type":"text","content":"\nCREXONT now available in U.S. pharmacies nationwide\n\nComprehensive access and affordability services to be made available to Parkinson’s patients and healthcare providers\n\nAmneal to hold CREXONT launch symposium and scientific presentations at the International Congress of Parkinson’s Disease and Movement Disorders on Sept. 27 – Oct. 1, 2024\n\n BRIDGEWATER, N.J.--(BUSINESS WIRE)--\nAmneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has launched CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease. CREXONT® is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release granules and extended-release pellets. CREXONT is now broadly available at U.S. pharmacies.\n\n“We are pleased to launch CREXONT and make it broadly available to healthcare providers and patients. The product’s innovative formulation provides a longer duration of “Good On” time with less frequent dosing compared to immediate release CD/LD. As a leader in the Parkinson’s space, Amneal has a long history of working closely with movement disorder specialists and neurologists. We are excited to build on this foundation with the rollout of a comprehensive education program and extensive services to help healthcare providers and patients access this innovative therapy,” said Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty.\n\nInformation for Physicians and Patients:\n\n\nCREXONT is available only through prescription.\n\n\nAmneal sales representatives will begin scheduling appointments with healthcare providers on Sept. 23, 2024.\n\n\nSamples of CREXONT will be available to healthcare providers beginning on Sept. 23, 2024.\n\n\nEligible commercially insured patients may qualify for a $25 copay on their prescriptions, applied automatically for most patients at the pharmacy through the CREXONT Savings Program.\n\n\nEligible patients will be able to have their CREXONT prescriptions covered through the Amneal Patient Assistance Program.\n\n\nCoverMyMeds® is a prior authorization (PA) solution that helps patients access CREXONT by streamlining the process for healthcare providers and pharmacists.\n\n\nAmneal understands the importance of access and affordability, particularly in the context of a new product launch. To supp...